Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

QRFP Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Serine365/Threonine368 phosphorylation of QRFP Receptor
pS365/pT368-QRFPR (phospho-QRFP Receptor Antibody)
Serine365/Threonine368 (S365/T368) is a major phosphorylation site of the QRFP receptor. The pS365/pT368-QRFPR antibody detects phosphorylation in response to high-efficacy agonists. S365/T368 phosphorylation is a key regulator of QRFPR...
$ 375.00 *
Details
NEW
Agonist-induced Serine377 phosphorylation of QRFP Receptor
pS377-QRFPR (phospho-QRFP Receptor Antibody)
Serine377 (S377) is a major phosphorylation site of the QRFP receptor. The pS377-QRFPR antibody detects phosphorylation in response to high-efficacy agonists. S377 phosphorylation is a key regulator of QRFPR desensitization, β-arrestin...
$ 375.00 *
Details

QRFP receptor was identified as a Gs-coupled GPCR that is activated by the endogenous pRFamide peptides QRFP43 (43RFa) and QRFP26 (26RFa). It is predominantly expressed in the brain, particularly in the thalamus, hypothalamus and pituitary. In mice, i.c.v. administration of QRFP26 or QRFP43 stimulates food intake and causes obesity. Central injection of QRFP43 has been shown to stimulate locomotor activity and to elevate arterial blood pressure. QRFP26 has also been proposed to play a role peripherally, in bone formation. QRFPR knockout mice have been shown to develop osteopenia. QRFP receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine365/threonine368 (pS365/pT368-QRFPR) and serine377 (pS377-QRFPR)). This nomenclature refers to the human QRFP receptor but is highly conserved in mice and rats. For more information on QRFPR receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Bagnol D, Bonner TI, Carlebur M, Davenport AP, Foord SM, Fukusumi S, Granata R, Larhammar D, Leprince J, Maguire JJ, Primeaux SD, Vaudry H. QRFP receptor in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F54/2023.1.

 

QRFP receptor was identified as a Gs-coupled GPCR that is activated by the endogenous pRFamide peptides QRFP43 (43RFa) and QRFP26 (26RFa). It is predominantly expressed in the brain,... read more »
Close window
QRFP Receptor Antibodies

QRFP receptor was identified as a Gs-coupled GPCR that is activated by the endogenous pRFamide peptides QRFP43 (43RFa) and QRFP26 (26RFa). It is predominantly expressed in the brain, particularly in the thalamus, hypothalamus and pituitary. In mice, i.c.v. administration of QRFP26 or QRFP43 stimulates food intake and causes obesity. Central injection of QRFP43 has been shown to stimulate locomotor activity and to elevate arterial blood pressure. QRFP26 has also been proposed to play a role peripherally, in bone formation. QRFPR knockout mice have been shown to develop osteopenia. QRFP receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine365/threonine368 (pS365/pT368-QRFPR) and serine377 (pS377-QRFPR)). This nomenclature refers to the human QRFP receptor but is highly conserved in mice and rats. For more information on QRFPR receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Bagnol D, Bonner TI, Carlebur M, Davenport AP, Foord SM, Fukusumi S, Granata R, Larhammar D, Leprince J, Maguire JJ, Primeaux SD, Vaudry H. QRFP receptor in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F54/2023.1.

 

Recently viewed